Medis Technologies Requests Information from SEC and DTC
Oct 8, 2007 7:30:00 AM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
Medis Technologies Ltd. (NASDAQ:MDTL) ("Medis") announced today that its
counsel has submitted a letter to the United States Securities and Exchange
Commission requesting under the Freedom of Information Act that the
Commission provide Medis with the most current delivery failure data
reported by banks and brokerage firms, including but not limited to short
sales and open settlements, relating to Medis' common stock.
Medis' counsel today also submitted a letter to the Depository Trust Company
requesting that the DTC perform an accounting regarding the number of shares
of Medis common stock held in its custody, to determine whether its records
reflect the correct number of shares outstanding.
Upon receipt of information from the SEC and DTC regarding short sales, open
settlements, and the number of shares in custody, Medis will review the data
in order to resolve errors in its share count, if any, and intends promptly
to take any and all action it deems appropriate to address failures of
market participants to cover short sales as required by the federal
securities laws.Medis Technologies' primary focus is on direct liquid fuel cell technology.
Its business strategy is to sell its products to end users through retail
outlets, service providers and to the military and other markets. Medis has
also developed the CellScan with many potential applications relating to
disease diagnostics and chemo sensitivity. Additionally, Medis' product
pipeline includes other technologies, in varying stages of development.
This press release may contain forward-looking statements, which are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. In some cases you can identify those so-called "forward
looking statements" by words such as "may," "will," "should," "expects,"
plans," "targets," "believes," "anticipates," "estimates," "predicts,"
"potential," or "continue" or the negative of those words and other
comparable words. These forward looking statements are subject to risks and
uncertainties, product tests, commercialization risks, availability of
financing and results of financing efforts that could cause actual results
to differ materially from historical results or those anticipated. Further
information regarding these and other risks is described from time to time
in the Company's filings with the SEC. We assume no obligation to update or
alter our forward-looking statements made in this release or in any periodic
report filed by us under the Securities Exchange Act of 1934 or any other
document, whether as a result of new information, future events or
otherwise, except as otherwise required by applicable federal securities
laws.
This press release is available on Medis' web site at
www.medistechnologies.com.
Source: Medis Technologies Ltd.